Brief: Bone Therapeutics FY Net Loss Down At 12.8 Million Euros

Biosenic SA

25/04/2018 06:14

April 25 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * STRONG CLINICAL PROGRESS IN ALLOB SPINAL FUSION AND
DELAYED
UNION TRIALS
    * LEADERSHIP TEAM STRENGTHENED WITH APPOINTMENTS OF JEAN
STÉPHENNE
AS CHAIRMAN OF THE BOARD (POST PERIOD) AND JEAN-LUC VANDEBROEK
AS CFO
    * FY NET LOSS OF EUR 12.8 MILLION VERSUS LOSS OF EUR 13.0
MILLION
YEAR AGO
    * EXCLUSIVE LICENSING AGREEMENT SIGNED WITH ASAHI KASEI FOR
DEVELOPMENT AND COMMERCIALIZATION OF PREOB IN JAPAN
    * FY OPERATING  LOSS EUR 12.3 MILLION VERSUS LOSS OF EUR
12.8
MILLION YEAR AGO
    * € 19.45 MILLION OF COMMITMENT SECURED FOLLOWING PRIVATE
PLACEMENT OF CONVERTIBLE BONDS (POST PERIOD)
    * CASH AT END OF Q4 EUR  8.41 MILLION VERSUS EUR 20.3
MILLION YEAR
AGO
    * BONE THERAPEUTICS PLANS TO REPORT THE FINAL RESULTS FROM
THE
ALLOB® PHASE I/IIA DELAYED-UNION STUDY IN MID-2018.
    * A VALUE INFLECTION POINT IS ANTICIPATED IN THE SECOND HALF
OF
2018,
    * CASH BURN FOR THE FULL YEAR OF 2018 IS EXPECTED TO BE IN
THE
RANGE OF € 15-16 MILLION
    * CO WILL HAVE SUFFICIENT CASH TO CARRY OUT ITS OBJECTIVES
UNTIL
END Q3 2019
    * CASH AT END OF Q4 EUR 8.41 MILLION VERSUS EUR 20.3 MILLION
YEAR
AGO

Source text : https://bit.ly/2qVTnTP
Further company coverage:  BOTHE.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))